- In May 2024, AstraZeneca and Daiichi Sankyo announced the expansion of their European clinical trial footprint for Enhertu (trastuzumab deruxtecan), targeting HER2-low breast cancer and non-small cell lung cancer patients. This development underscores the companies’ commitment to advancing ADC research across key EU countries, including Germany, France, and Spain, while broadening patient access to next-generation targeted therapies in the region
- In April 2024, ADC Therapeutics SA, headquartered in Switzerland, partnered with Italian cancer research institutions to initiate Phase II trials of its novel CD25-targeting ADC in relapsed Hodgkin lymphoma. The collaboration reflects a growing emphasis on region-specific oncology trials and reinforces the role of European clinical networks in accelerating ADC innovation
- In March 2024, the European Medicines Agency (EMA) granted accelerated assessment status to ImmunoGen’s Elahere (mirvetuximab soravtansine) for treating platinum-resistant ovarian cancer. This milestone highlights the EMA’s growing support for breakthrough ADC therapies and is expected to fast-track regulatory review and availability across EU member states
- In February 2024, the U.K.’s National Institute for Health and Care Excellence (NICE) issued a positive draft recommendation for Polivy (polatuzumab vedotin) in combination therapies for diffuse large B-cell lymphoma (DLBCL). The move signals strong national backing for integrating ADCs into standard treatment regimens and expanding patient access to advanced biologics
- In January 2024, Germany-based BioNTech SE announced its entry into the ADC space through a strategic acquisition of a European biotech specializing in site-specific conjugation technologies. The acquisition aims to strengthen BioNTech’s oncology pipeline and underscores the growing interest among European biopharma leaders in ADC platforms as a key focus area for targeted cancer treatment
